

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND INSIDE INFORMATION AND RESUMPTION OF TRADING**

This announcement is made by the board of directors of Yestar Healthcare Holdings Company Limited (“**Company**”) pursuant to Rule 13.09 and Rule 13.10 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the Inside Information Provisions (the “**Inside Information Provisions**”) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has noted the drop in the price and the increase in trading volume of the shares of the Company (the “**Shares**”) today. Having made such enquiry with respect to the Company as may be reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of any reason for such Share price and volume movements or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under the Inside Information Provisions.

After due enquiry by the Board, the Company was notified that a total of 64,140,000 Shares (the “**Sold Shares**”) (which were placed in two securities trading accounts with margin facilities) held by our non-executive Director, Mr. Hartono James (“**Mr. Hartono**”), representing approximately 2.8% of the total issued share capital of the Company were sold on the market. As confirmed by Mr. Hartono, the Sold Shares were disposed by the securities firms holding the securities trading accounts under margin financing arrangements.

The Board confirms that the Group's business operation remains normal, and that there is no material adverse change to the business operation and financial position of the Group as a result of the disposal of the Sold Shares.

At the request of the Company, trading in the Shares on the Stock Exchange has been halted with effect from 1:32 p.m. on Thursday, 28 December 2023. Application has been made by the Company for resumption of trading in its Shares on the Stock Exchange with effect from 9:00 a.m. on 29 December 2023.

Shareholders of the Company, noteholders and other investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Liao Changxiang**  
*CEO and executive Director*

Hong Kong, 28 December 2023

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.*